Novartis: presents results for MS drug
(CercleFinance.com) - Novartis will present data to ACTRIMS-ECTRIMS for Kesmimpta (ofatumumab) in newly diagnosed naïfs de traitement adults with recurring multiple sclerosis.
This data still supports Kesmpta as a primary treatment option for adults with RMS.
This encouraging data shows that newly diagnosed untreated patients may benefit from reduced disease activity when treated with Kesimpta, said Dr. Amit Bar-Or, from the University of Pennsylvania.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This data still supports Kesmpta as a primary treatment option for adults with RMS.
This encouraging data shows that newly diagnosed untreated patients may benefit from reduced disease activity when treated with Kesimpta, said Dr. Amit Bar-Or, from the University of Pennsylvania.
Copyright (c) 2020 CercleFinance.com. All rights reserved.